BioLamina
Develops and supplies recombinant laminin-based cell culture matrices and bioinks for 3D bioprinting and stem cell research, enabling biologically relevant 3D cell culture environments.
- CEO / Founder
- Veronica Byfield Sköld
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $20.36M
- Latest Round
- Venture Round
- Key Investors
- Lauxera Capital Partners
Technology & Products
Key Products
Biolaminin® isoforms; Biosilk 3D culture matrix; Bioink products (via partnerships)
Technological Advantage
Scientifically proven to increase cell proliferation rates with stable phenotype; only provider of full-length, human recombinant laminins; materials are defined, xeno-free, and regulatory-compliant.
Differentiation
Value Proposition
Provides defined, animal-origin-free laminin matrices that improve cell proliferation, differentiation, and phenotype stability in 2D and 3D cultures, accelerating stem cell research and therapy development.
How They Differentiate
Offers full-length human recombinant laminins (vs. animal-derived or fragment-based alternatives) with proven efficacy in 3D bioprinting applications; partnerships with leading bioprinter manufacturers like CELLINK provide integrated bioink solutions.
Market & Competition
Target Customers
Research institutions, biopharmaceutical companies, cell therapy developers, and bioprinting companies
Industry Verticals
Biotechnology; Pharmaceuticals; Regenerative Medicine; Research
Competitors
Corning Matrigel; Thermo Fisher Scientific; STEMCELL Technologies; R&D Systems
Growth & Milestones
Growth Metrics
About 20 employees spanning production, R&D, logistics, sales, and marketing; global presence with offices in Sweden and USA.
Major Milestones
Founded in 2008; Partnership with CELLINK for bioink development (2020s); €17M investment from Lauxera Capital Partners (2023); Strategic partnerships with Pluristyx and Cell X Technologies
Notable Customers
Pluristyx; Inventia Life Science; FyoniBio; Alder Therapeutics